Answers are grounded in this paper and cite their sources.
Background: Cholecystokinin and gastrin are endocrine growths factors for certain tumours and CCK 1 R and CCK2R receptors are ideal molecular targets for novel smart chemotherapeutics with a beneficial overall profile due to their anxiolytic and antidepressant properties. Lung cancers are fuelled by gastrin and therefore, selective gastrin (CCK 2 R) antagonists are ideal experimental drug candidates.
No takes yet. Share an insight, caveat, or question.
Eric Lattmann (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: